Appili Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLIF research report →
Price Chart
About the company
Appili Therapeutics, Inc. is a biopharmaceutical company, which engages in acquisition and development of novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as LIKMEZ, ATI-1701 and ATI-1801.
- CEO
- Don Cilla
- IPO
- 2021
- Employees
- 7
- HQ
- Halifax, NS, CA
Get TickerSpark's AI analysis on APLIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $244.81K+143.7%
- Gross Profit
- $236.70K+135.7%
- Op Income
- $-6,550,229
- Net Income
- $-4,251,698-62.0%
- EPS
- $-0.03-59.3%
- OCF Growth
- -259.7%
- FCF Growth
- -260.2%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.21
- RSI (14)
- 15
- Avg Volume
- 3.27K
No earnings-call transcripts are available for APLIF yet.
- Free Float
- 73.9%
- Shares Outstanding
- 132.37M
- Float Shares
- 97.81M
Our APLIF coverage
Recent articles, reports, and earnings notes.
No research on APLIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APLIF report →Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2027
newsfilecorp.com · Nov 12
Appili Therapeutics Announces Transfer to NEX
newsfilecorp.com · Sep 29
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
newsfilecorp.com · Aug 14
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
globenewswire.com · Jul 3
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
globenewswire.com · Jun 26
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
globenewswire.com · Mar 30
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
globenewswire.com · Feb 18
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
globenewswire.com · Feb 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.